

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
Manfred SCHUDOK et al.)	Group Art Unit: Not Assigned Yet
)	
Application No.: Not Assigned Yet)	Examiner: Not Assigned Yet
)	
Filed: August 6, 2003)	
)	
For: MALONAMID AND MALONAMIC)	
ESTER DERIVATIVES WITH)	
ANTITHROMBOTIC ACTIVITY,)	
THEIR PREPARATION, AND)	
THEIR USE)	

Commissioner for Patents and Trademarks
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed concurrently with the filing of a Divisional Application under 37 C.F.R. § 1.53(b) and before the mailing of a first Office Action.

A copy of prior application, Application No. 09/965,790 (Pub. No.: US 2003/0027828 A1), filing date October 1, 2001, is attached. Copies of the other listed documents were made of record during prosecution of Application No. 09/965,790, upon which Applicants rely for the benefits provided in 35 U.S.C. § 120. Applicants respectfully request that the Examiner consider the listed documents and

indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: August 6, 2003

By: 

Aaron M. Raphael
Reg. No. 47,885

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	2481.1762-01	Serial No.	Not Assigned Yet
Applicant	Manfred SCHUDOK et al.		
Filing Date	August 6, 2003	Group:	Not Assigned Yet

U.S. PATENT DOCUMENTS							
Examiner Initial*		Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
		Pub. No.: US 2003/0027828 A1		SCHUDOK et al.			10/01/2001

FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
		00/01704 A	01/13/2000	WO			No
		97/49684 A	12/31/1997	WO			
		97/48706 A	12/24/1997	WO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	H. Cole, "The tissue factor pathway of coagulation," <i>Aust. J. Med. Sci.</i> , 16:87-93 (1995).
	G. J. Broze, Jr., "Tissue factor pathway inhibitor and the current concept of blood coagulation," <i>Blood Coagulation and Fibrinolysis</i> , 6 (Suppl. 1):S7-S13 (1995).
	L. A. Harker et al., "Antithrombotic and Antilesion Benefits without Hemorrhagic Risks by Inhibiting Tissue Factor Pathway," <i>Haemostasis</i> , 26 (Suppl. 1):76-82 (1996).
	L. A. Harker et al., "Antithrombotic Benefits and Hemorrhagic Risks of Direct Thrombin Antagonists," <i>Thrombosis and Haemostasis</i> , 74(1):464-472 (1995).
	Y. Cheng and W. H. Prusoff, "Relationship Between the Inhibition Constant (K_i) and the Concentration of Inhibitor Which Causes 50 Per Cent Inhibition (I_{50}) of an Enzymatic Reaction," <i>Biochem. Pharmacol.</i> , 22:3099-3108 (1973).
	I. H. Segel, ENZYME KINETICS: BEHAVIOR AND ANALYSIS OF RAPID EQUILIBRIUM AND STEADY-STATE ENZYME SYSTEMS 100-125 (John Wiley & Sons, New York 1975).
	J. A. Ostrem et al., "Discovery of a Novel, Potent, and Specific Family of Factor Xa Inhibitors via Combinatorial Chemistry," <i>Biochemistry</i> , 37:1053-1059 (1998).

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	2481.1762-01	Serial No.	Not Assigned Yet
Applicant	Manfred SCHUDOK et al.		
Filing Date	August 6, 2003	Group:	Not Assigned Yet

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	J. E. Hall et al., "Anti- <i>Pneumocystis</i> Activities of Aromatic Diamidoxime Prodrugs," <i>Antimicrobial Agents and Chemotherapy</i> , 42(3):666-674 (1998).
	G. E. Davies and J. S. Lowe, "The Inhibition of Guinea-Pig Plasma Kallikrein by Amidines," <i>Advances in Experimental Medicine and Biology</i> , 8:453-460 (1970).
	International Search Report for International Application No. PCT/EP 01/10845 (Nov. 27, 2001).
	Geratz et al., "Diamidino- α,ω -diphenoxyalkanes. Structure-Activity Relationships for the Inhibition of Thrombin, Pancreatic Kallikrein, and Trypsin," <i>Journal of Medicinal Chemistry</i> 16(9):970-975 (1973).
	Rauch et al., "Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences," <i>Ann. Intern. Med.</i> , 134(3):224-238 (2001).
	Van Aken et al., "Anticoagulation: the present and future," <i>Clin. Appl. Thromb. Hemost.</i> , 7(3):195-204 (2001).

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce